Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robyn Clark

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Heart, Lung & Circulation|August 30, 2020
CSANZ COVID-19 Cardiovascular Nursing Care Consensus Statement: Executive SummarySally C Inglis, Carolyn Naismith, Kevin White, et al.
Journal of Medical Internet Research|March 12, 2026
Creation of EmpowerMe Website to Promote Self-Efficacy in Survivors of Stroke: Co-Design StudyElizabeth A Lynch, Adrian O'Malley, Zoe Adey-Wakeling, et al.
Molecular Cancer Therapeutics|February 4, 2021
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian CancerAmy A Lo, Jennifer Johnston, Ji Li, et al.
Cancer Research|September 18, 2014
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Development and preclinical characterization of a humanized antibody targeting CXCL12Cuiling Zhong, Jianyong Wang, Bing Li, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Science Translational Medicine|May 15, 2015
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.
JCI Insight|April 10, 2020
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibodyKarin Staflin, Christina L Zuch de Zafra, Leah K Schutt, et al.
Molecular Cancer Therapeutics|April 1, 2022
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal CancerPeiyin Wang, Liping L Sun, Robyn Clark, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2024
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunityAurelie Herault, Judy Mak, Josefa de la Cruz-Chuh, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Heart, Lung & Circulation|August 30, 2020
CSANZ COVID-19 Cardiovascular Nursing Care Consensus Statement: Executive SummarySally C Inglis, Carolyn Naismith, Kevin White, et al.
Journal of Medical Internet Research|March 12, 2026
Creation of EmpowerMe Website to Promote Self-Efficacy in Survivors of Stroke: Co-Design StudyElizabeth A Lynch, Adrian O'Malley, Zoe Adey-Wakeling, et al.
Molecular Cancer Therapeutics|February 4, 2021
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian CancerAmy A Lo, Jennifer Johnston, Ji Li, et al.
Cancer Research|September 18, 2014
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Development and preclinical characterization of a humanized antibody targeting CXCL12Cuiling Zhong, Jianyong Wang, Bing Li, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Science Translational Medicine|May 15, 2015
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.
JCI Insight|April 10, 2020
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibodyKarin Staflin, Christina L Zuch de Zafra, Leah K Schutt, et al.
Molecular Cancer Therapeutics|April 1, 2022
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal CancerPeiyin Wang, Liping L Sun, Robyn Clark, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2024
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunityAurelie Herault, Judy Mak, Josefa de la Cruz-Chuh, et al.
Pageof 6